| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash provided by (used in) financing activities | 15,875 | 14,499 |
| Effect of exchange rate changes on cash | 153 | 194 |
| Net increase (decrease) in cash and cash equivalents | 240 | 10,614 |
| Cash and cash equivalents at beginning of period | 6,212 | - |
| Cash and cash equivalents at end of period | 6,452 | - |
Quince Therapeutics, Inc. (QNCX)
Quince Therapeutics, Inc. (QNCX)